HC Wainwright Issues Positive Outlook for Celcuity Earnings

Celcuity Inc. (NASDAQ:CELC - Free Report) - Stock analysts at HC Wainwright increased their Q2 2025 earnings per share estimates for Celcuity in a research report issued on Monday, May 19th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.99) for the quarter, up from their previous forecast of ($1.04). HC Wainwright has a "Buy" rating and a $27.00 price target on the stock. The consensus estimate for Celcuity's current full-year earnings is ($2.62) per share. HC Wainwright also issued estimates for Celcuity's Q3 2025 earnings at ($1.02) EPS, Q4 2025 earnings at ($1.05) EPS, FY2025 earnings at ($3.92) EPS, FY2026 earnings at ($4.11) EPS and FY2027 earnings at ($0.94) EPS.

Separately, Needham & Company LLC restated a "buy" rating and issued a $29.00 price objective on shares of Celcuity in a report on Thursday, May 15th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Celcuity currently has a consensus rating of "Buy" and an average target price of $30.80.

Celcuity Stock Down 2.9%

CELC traded down $0.31 during trading on Wednesday, reaching $10.44. The company had a trading volume of 144,757 shares, compared to its average volume of 299,449. The business's fifty day moving average price is $10.19 and its 200 day moving average price is $11.47. Celcuity has a 12 month low of $7.58 and a 12 month high of $19.77. The company has a market cap of $395.32 million, a P/E ratio of -4.00 and a beta of 0.56. The company has a debt-to-equity ratio of 0.65, a current ratio of 10.35 and a quick ratio of 10.36.

Celcuity (NASDAQ:CELC - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.86) EPS for the quarter, topping analysts' consensus estimates of ($0.95) by $0.09.

Institutional Trading of Celcuity

A number of institutional investors and hedge funds have recently bought and sold shares of CELC. Summit Investment Advisors Inc. grew its position in shares of Celcuity by 49.5% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,421 shares of the company's stock worth $45,000 after buying an additional 1,132 shares during the period. Aquatic Capital Management LLC bought a new position in shares of Celcuity in the fourth quarter valued at $50,000. Focus Financial Network Inc. acquired a new stake in shares of Celcuity in the 1st quarter worth about $108,000. Perkins Capital Management Inc. bought a new position in Celcuity in the 1st quarter valued at about $115,000. Finally, GAMMA Investing LLC boosted its stake in Celcuity by 1,237.4% during the 1st quarter. GAMMA Investing LLC now owns 1,324 shares of the company's stock valued at $131,000 after purchasing an additional 1,225 shares during the last quarter. 63.33% of the stock is currently owned by institutional investors and hedge funds.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.